BIOMAT Database Logo BIOMAT Database Logo

Uraemic and normal plasma protein binding of various cardiac glycosides under "in vivo" conditions. 1974

P Kramer, and E Köthe, and F Scheler

UI MeSH Term Description Entries
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D010042 Ouabain A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. Acocantherin,G-Strophanthin,Acolongifloroside K,G Strophanthin
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002301 Cardiac Glycosides Cyclopentanophenanthrenes with a 5- or 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. Plants they come from have long been used in congestive heart failure. They increase the force of cardiac contraction without significantly affecting other parameters, but are very toxic at larger doses. Their mechanism of action usually involves inhibition of the NA(+)-K(+)-EXCHANGING ATPASE and they are often used in cell biological studies for that purpose. Cardiac Glycoside,Cardiotonic Steroid,Cardiotonic Steroids,Glycoside, Cardiac,Glycosides, Cardiac,Steroid, Cardiotonic,Steroids, Cardiotonic
D004074 Digitoxin A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) Coramedan,Digimed,Digimerck,Digitaline Nativelle,Digitoxin AWD,Digitoxin Bürger,Digitoxin Didier,Digitoxin-Philo,Digophton,AWD, Digitoxin,Bürger, Digitoxin,Didier, Digitoxin,Digitoxin Philo,Nativelle, Digitaline
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013328 Strophanthins A number of different cardioactive glycosides obtained from Strophanthus species. OUABAIN is from S. gratus and CYMARINE from S. kombe. They are used like the digitalis glycosides. Strophanthin

Related Publications

P Kramer, and E Köthe, and F Scheler
[Binding of various cardiac glycosides to plasma proteins].
January 1968, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,
P Kramer, and E Köthe, and F Scheler
[Plasma protein binding of cardiac glycosides in limited kidney function].
January 1974, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
P Kramer, and E Köthe, and F Scheler
[Serum level and excretion of H3 labeled cardiac glycosides under normal and pathological conditions].
January 1969, Radiobiologia, radiotherapia,
P Kramer, and E Köthe, and F Scheler
Protein binding of piretanide in normal and uraemic serum.
January 1982, European journal of clinical pharmacology,
P Kramer, and E Köthe, and F Scheler
[Changes in the binding properties of plasma proteins in plasma stored under various conditions].
January 1969, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,
P Kramer, and E Köthe, and F Scheler
[Specific tritiation of cardiac glycosides under Wilzbach conditions].
June 1969, Die Naturwissenschaften,
P Kramer, and E Köthe, and F Scheler
Phagocytosis in Vivo under various Conditions.
September 1917, The Journal of medical research,
P Kramer, and E Köthe, and F Scheler
[Long-term use of cardiac glycosides under ambulatory conditions].
January 1978, Terapevticheskii arkhiv,
P Kramer, and E Köthe, and F Scheler
Protein binding of cardiac glycosides in disease states.
January 1977, Clinical pharmacokinetics,
P Kramer, and E Köthe, and F Scheler
Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions.
May 2001, Clinical endocrinology,
Copied contents to your clipboard!